Mesoblast Limited (NASDAQ:MESO) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Mesoblast Limited (NASDAQ:MESO) have been assigned a consensus recommendation of “Hold” from the six research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $13.67.

A number of research analysts have recently issued reports on MESO shares. StockNews.com downgraded Mesoblast from a “hold” rating to a “sell” rating in a report on Tuesday, April 2nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a report on Friday, January 12th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of MESO. Envestnet Asset Management Inc. bought a new position in shares of Mesoblast in the third quarter worth about $33,000. EWA LLC bought a new position in shares of Mesoblast in the first quarter worth about $40,000. Prosperity Wealth Management Inc. bought a new position in shares of Mesoblast in the third quarter worth about $79,000. Vident Investment Advisory LLC raised its stake in shares of Mesoblast by 12.8% in the fourth quarter. Vident Investment Advisory LLC now owns 28,080 shares of the company’s stock worth $82,000 after buying an additional 3,191 shares during the period. Finally, Marshall Wace LLP bought a new position in shares of Mesoblast in the fourth quarter worth about $85,000. Institutional investors own 1.43% of the company’s stock.

Mesoblast Price Performance

Shares of NASDAQ:MESO opened at $5.73 on Friday. The company has a market cap of $653.63 million, a P/E ratio of -5.12 and a beta of 3.60. Mesoblast has a 1 year low of $1.61 and a 1 year high of $10.24. The stock’s fifty day moving average price is $2.99 and its 200-day moving average price is $2.50.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.